Skip to main content
SpringerLink
Log in

Psychostimulanzien

  • Chapter
Neuro-Psychopharmaka im Kindes- und Jugendalter

Zusammenfassung

Als Psychostimulanzien, Stimulanzien, Psychotonika oder Psychoanaleptika wird die Gruppe von Neuro-Psychopharmaka bezeichnet, die vorwiegend eine erregende Wirkung auf die Psyche ausüben. Sie sollen das Gefühl von Müdigkeit und Abgespanntheit beseitigen sowie die Konzentrations- und Leistungsfähigkeit erhöhen. Wir möchten hier noch einmal betonen, dass die Einteilung der Neuro-Psychopharmaka sich an den psychopathologischen Symptomen, die durch die Wirkstoffe beeinflusst werden, orientiert und unabhängig ist von den unterschiedlichen neuro-psychiatrischen Erkrankungen, bei denen sie auftreten können.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  • Bandelow B, Heise CA, Banaschewski T, Rothenberger A (2006) Handbuch Psychopharmaka für das Kindes-und Jugendalter. Deutsche Überarbeitung von Bezchlibnyk-Butler KZ, Virani AS (eds) Clinical handbook of psychotropic drugs for children and adolescents. Hogrefe Verlag, Göttingen Bonn Bern Wien

    Google Scholar 

  • Bezchlibnyk-Butler KZ, Virani AS (2007) (eds) Clinical handbook of psychotropic drugs for children and adolescents. Second revised edition. Hogrefe & Hubers Publishers, Cambridge Göttingen Bern

    Google Scholar 

  • Iversen L (ed) (2006) Speed, ecstasy, ritalin. The science of amphetamines. University Press, Oxford

    Google Scholar 

  • Nissen G, Fritze J, Trott G-E (2004) (Hrsg) Psychopharmaka im Kindes-und Jugendalter. Urban & Fischer Verlag, München Jena

    Google Scholar 

  • Riederer P, Laux G (Hrsg) (2005) Neuro-Psychopharmaka Bd. 6, Notfalltherapie, Antiepileptika, Psychostimulantien, Suchttherapeutika und sonstige Psychopharmaka, 2. Aufl. Springer, Wien New York

    Google Scholar 

Ausgewählte Literatur

  • AACCP Official Action (2002) Practice paramater for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry [Suppl 2] 41: 26S–49S

    Google Scholar 

  • Ahmann PA, Theye FW, Berg R, Linquist AJ, Van Erem AJ, Campbell LR (2001) Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects. Pediatrics 107: E10

    Article  PubMed  CAS  Google Scholar 

  • Albayrak Ö, Friedel S, Schimmelmann BG, Hinney A, Hebebrand J (2008) Genetic aspects in attention-deficit/hyperactivity disorder. J Neural Transm 115: 305–315

    Article  PubMed  CAS  Google Scholar 

  • Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S (2008) Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 32: 145–149

    Article  PubMed  CAS  Google Scholar 

  • Andersen SL, Arvanitogiannis A, Pliakas AM, LeBlanc C, Carlezon WA (2002) Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci 5: 13–14

    Article  PubMed  CAS  Google Scholar 

  • Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen H-C, Sonuga-Barke EJS, Taylor E (2008) Langwirksame Medikamente zur Behandlung der hyperkinetischen Störungen (Teil 1 und 2). Z Kinder Jugendpsychiatr Psychother 36: 81–107

    Article  PubMed  Google Scholar 

  • Bangs ME, Jin L, Zhang S, Desaiah D, Allen AJ, Read HA, Regev A, Wernicke JF (2008a) Hepatic events associated with atomoxetine treatment for attention deficit hyperactivity disorder. Drug Saf 31: 345–354

    Article  PubMed  CAS  Google Scholar 

  • Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, Trzepacz PT, Allen AJ (2008b) Meta-analysis of suicide-related behayior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 47: 209–218

    Article  PubMed  Google Scholar 

  • Baxter K (ed) (2007) Stockley’s drug interactions, 8th edn. Pharmaceutical Press, London Chicago

    Google Scholar 

  • Behar D, Schaller J, Spreat S (1998) Extreme reduction of methylphenidate levels by carbamazepine. J Am Acad Child Adolesc Psychiatry 37: 1128–1129

    Article  PubMed  CAS  Google Scholar 

  • Biederman J, Pliszka SR (2008) Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr 152: 394–399

    Article  PubMed  CAS  Google Scholar 

  • Biederman J, Wilens T, Mick E, Spencer T, Faraone SV (1999) Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104: E201–E205

    Article  Google Scholar 

  • Biederman J, Monuteaux MC, Spencer T, Wilens T, MacPherson HA, Faraone SV (2008) Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 165: 597–603

    Article  PubMed  Google Scholar 

  • Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, Fagan J, Gadoros J, Harpin V, Hazell P, Johnson M, Lerman-Sagie T, Soutullo CA, Wolanczyk T, Zeiner P, Fouche DS, Krikke-Workel J, Zhang S, Michelson D; Atomoxetine International Study Group (2004) A prospective, multicenter, open-lapel assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 13: 249–257

    PubMed  Google Scholar 

  • Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, Rapoport JL (1997) Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 36: 589–596

    Article  PubMed  CAS  Google Scholar 

  • Chouinard G, Annable L, Bradwein J (1984) An early phase II clinical trial of tomoxetine (LY 139603) in the treatment of newly admitted depressed patients. Psychopharmacology 83: 126–128

    Article  PubMed  CAS  Google Scholar 

  • Döpfner M, Lehmkuhl G (2002) Evidenzbasierte Therapie von Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS). Praxis Kinderpsychol Kinderpsychiatr 61: 419–440

    Google Scholar 

  • Döpfner M, Banaschewski T, Schmidt J, Uebel H, Schmeck K, Gerber WD, Günter M, Knölker U, Gehrke M, Häßler F, Möhler E, Brünger M, Ose C, Rischer R, Poustka F, Lehmkuhl F, Rotenberger A (2003) Langzeitwirksames Methylphenidat bei Kindern mit Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen. Eine multizentrische Studie. Nervenheilkunde 22: 85–92

    Google Scholar 

  • Döpfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von Müller G, Günter M, Hässler F, Ose C, Rothenberger A, Schmeck K, Sinzig J, Stadler C, Uebel H, Lehmkuhl G (2004) Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry [Suppl 1]: 93–101

    Google Scholar 

  • Döpfner M, Lehmkuhl G, Schepker R, Frölich J (2007) Hyperkinetische Störungen (F90) In: Deutsche Gesellschaft für Kinder-und Jugendpsychiatrie und Psychotherapie, Bundesarbeitsgemeinschaft Leitender Klinikärzte für Kinder-und Jugendpsychiatrie und Psychotherapie und Bundesverband der Ärzte für Kinder-und Jugendpsychiatrie und Psychotherapie (Hrsg) Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes-und Jugendalter. 3. überarb. und erw. Aufl. Deutscher Ärzte-Verlag, Köln, 239–254

    Google Scholar 

  • Drugdex drug evaluations (2008) Medizinisches Informations-System 136: 6

    Google Scholar 

  • El-Zein RA, Abdel-Rahman SZ, Hay MJ, Lopez MS, Bondy ML, Morris DL, Legator MS (2005) Cytogenetic effects in children treated with methylphenidate. Cancer Lett 230: 284–291

    Article  PubMed  CAS  Google Scholar 

  • Faraone SV, Biederman J, Spencer TJ, Aleardi M (2006) Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 5:8: 4

    Google Scholar 

  • Faraone SV, Wigal SB, Hofgins P (2007) Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with ADHD. J Atten Disord 11: 74–82

    Article  PubMed  Google Scholar 

  • Fegert JM, Hebebrand J; Kommission Entwicklungspsychopharmakologie der drei Fachgesellschaften (2006) Stellungnahme zu fraglichen kardialen Risiken der Stimulanziengabe. Z Kinder Jugendpsychiatr Psychother 34: 295–297

    Article  PubMed  Google Scholar 

  • Gerlach M (2002) ADHS. Stimulanzien-Therapie: Gefahr für Kinder-und Jugendliche? Neuro-Transmitter 7–8: 69–72

    Google Scholar 

  • Gerlach M, Banaschewski T, Warnke A, Rothenberger A (2003) Ist ein Parkinson-Syndrom als Spätfolge einer Methylphenidat-Behandlung im Kindesalter möglich? Eine empirische Standortbestimmung. Nervenheilkunde 22: 80–84

    Google Scholar 

  • Ghuman JK, Ginsburg GS, Subramaniam G, Ghuman HS, Kau AS, Riddle MA (2001) Psychostimulants in preschool children with attention deficit/hyperactivity disorder: clinical evidence from a developmental disorder institution. J Am Acad Child Adolesc Psychiatry 40: 516–524

    Article  PubMed  CAS  Google Scholar 

  • Gibson AP, Bettinger TL, Patel NC, Crismon ML (2006) Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother 40: 1134–1142

    Article  PubMed  CAS  Google Scholar 

  • Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B, Eidevall-Wallin L, Gustafsson P, Kopp S (1997) Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 54: 857–864

    PubMed  CAS  Google Scholar 

  • Göthert M, Bönisch H, Schlicker E, Maier W (2005) Psychopharmaka — Pharmakotherapie psychischer Erkrankungen. In: Aktories K, Förstermann U, Hofmann FB, Starke K (2005) Allgemeine und spezielle Pharmakologie und Toxikologie, 9. Aufl. Urban & Fischer, München Jena, 313–317

    Google Scholar 

  • Greenhill LL, Halperin JM, Abikoff H (1999) Stimulant medications. J Am Acad Child Adolesc Psychiatry 38: 503–512

    Article  PubMed  CAS  Google Scholar 

  • Grob CS, Coyle JT (1986) Suspected adverse methylphenidate-imipramine interactions in children. J Dev Behav Pediatr 7: 265–267

    Article  PubMed  CAS  Google Scholar 

  • Gucuyener K, Erdemoglu AK, Senol S, Serdaroglu A, Soysal S, Kocker AI (2003) Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 18: 109–112

    Article  PubMed  Google Scholar 

  • Huss M, Lehmkuhl U (2002) Methylphenidate and substance abuse. A review of pharmacology, animal and clinical studies. J Attent Disorders [Suppl 1] 6: 53–59

    Google Scholar 

  • Huss M, Poustka F, Lehmkuhl G, Lehmkuhl U (2008) No increase in long-term risk for nicotine use disorders after treatment with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD): evidence from a non-randomised retrospective study. J Neural Transm 115: 335–339

    Article  PubMed  CAS  Google Scholar 

  • Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ (2004) Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 114: e1–8

    Article  PubMed  Google Scholar 

  • Kerdar MS, Scheuerpflug P, Srdinko P, Wewetzer Ch, Warnke A, Romanos M (2007) EEG-Veränderungen unter Methylphenidat — eine Pilotstudie. Z Kinder-Jugendpsychiatr 35: 247–255

    Article  Google Scholar 

  • Kimko HC, Cross JT, Abernethy DR (1999) Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 37: 457–470

    Article  PubMed  CAS  Google Scholar 

  • Krause J (2008) SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev Neurother 8: 611–625

    Article  PubMed  CAS  Google Scholar 

  • Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, Gelowitz DL (2006) Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45: 919–927

    Article  PubMed  Google Scholar 

  • Kurlan R (2002) Editorial. Methylphenidate to treat ADHD is not contraindicated in children with tics. Mov Disord 17: 5–6

    Article  PubMed  Google Scholar 

  • Kurlan R (2003) Tourette’s syndrome: are stimulants safe? Curr Neurol Neurosci Rep 3: 285–288

    Article  PubMed  Google Scholar 

  • Lahat E, Weiss M, Ben-Shlomo A, Evans SM, Bistritzer T (2000) Bone mineral density and turn-over in children with attention-deficit-hyperactivity disorder receiving methylphenidate. J Child Neurol 15: 436–439

    Article  PubMed  CAS  Google Scholar 

  • Lohse MJ, Lorenzen A, Müller-Oerlinghausen B (2006) Psychopharmaka. In: Schwabe U, Pfaffrath D (Hrsg) Arzneiverordnungs-Report 2006. Springer, Berlin Heidelberg New York, 852–854

    Google Scholar 

  • Madras BK, Miller GM, Fischman AJ (2005) The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 57: 1397–1409

    Article  PubMed  CAS  Google Scholar 

  • Mannuzza S, Klein RG, Truong NL, Moulton JL III, Roizen ER, Howell KH, Castellanos FX (2008) Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 165: 604–609

    Article  PubMed  Google Scholar 

  • Markowitz JS, Patrick KS (2001) Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 40: 753–771

    Article  PubMed  CAS  Google Scholar 

  • Mehler-Wex C, Riederer P, Gerlach M (2007) Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res 10: 167–179

    Article  Google Scholar 

  • Michelson D, Allen AJ, Busner J, Casat Ch, Dunn D, Kratochvil Ch, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatr 159: 1896–1901

    Article  PubMed  Google Scholar 

  • Mörike K, Gleiter Ch H (2005) Psychostimulanzien. Pharmakokinetik. In: Riederer P, Laux G (Hrsg) Neuro-Psychopharmaka Bd. 6, Notfalltherapie, Antiepileptika, Psychostimulantien, Suchttherapeutika und sonstige Psychopharmaka, 2. Aufl. Springer, Wien New York, 179–181

    Google Scholar 

  • MTA Cooperation Group (1999) A 14 month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal treatment Study of Children with ADHD. Arch Gen Psychiatry 56: 1073–1086

    Article  Google Scholar 

  • MTA Cooperation Group (2004) National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 113: 754–761

    Article  Google Scholar 

  • National Institutes of Health Consensus Development Conference Statement (2000) Diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 39: 182–193

    Article  Google Scholar 

  • Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey S M, Chronis AM, Forehand GL, Nguyen CA, Hoffmann MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD (2001) Once-a-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107: e105

    Article  PubMed  CAS  Google Scholar 

  • Perwien AR, Faries DE, Kratochvil CJ, Sumner CR, Kelsey DK, Allen AJ (2004) Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr 25: 264–271

    Article  PubMed  Google Scholar 

  • Pompidou-Group (2000) Attention Deficit/Hyerkinetic Disorders. Their diagnosis and treatment with stimulants. Council of Europe

    Google Scholar 

  • Poncin Y, Sukhodolsky DG, McGuire J, Scahill L (2007) Drug and non-drug treatments of children with ADHD and tic disorders. Eur Child Adolesc Psychiatry 16 [Suppl 1]: 78–88

    Article  PubMed  Google Scholar 

  • Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK, McCracken JT, Swanson JM, Hughes CW, Llana ME, Lopez M, Toprac MG (2000) The Texas children’s medication algorithm project: report of the texas consensus conference panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part I and II. Am Acad Child Adoles Psychiatry 39: 908–927

    Article  CAS  Google Scholar 

  • Preston RJ, Kollins SH, Swanson JM, Greenhill LL, Wigal T, Elliott GR, Vitiello B (2005) Comments on ‘Cytogenetic effects in children treated with methylphenidate’ by El-Zein et al. Cancer Lett 230: 292–294

    Article  PubMed  CAS  Google Scholar 

  • Rapport MD, Moffitt C (2002) Attention deficit/hyperacitivity disorder and methylphenidate. Re-view of height and weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 22: 1107–1131

    PubMed  Google Scholar 

  • Renner TJ, Gerlach M, Romanos M, Hermann M, Reif A, Fallgatter A, Lesch K-P (2008) Neurobiologie des Aufmerksamkeitsdefizit-/Hyperaktivitätssyndroms. Nervenarzt 79: 771–781

    Article  PubMed  CAS  Google Scholar 

  • Roessner V, Robatzek M, Knapp G, Banaschewski T, Rothenberger A (2006) First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol 48: 616–621

    Article  PubMed  Google Scholar 

  • Rothenberger A, Resch F (2002) Aufmerksamkeitsdefizit-Hyperaktivitätsstörung (ADHS) und Stimulantien. Editorial. Z Kinder-Jugendpsychiatr 30: 159–161

    Google Scholar 

  • Schaller JL, Behar D (1999) Carbamazepine and methylphenidate in ADHD. J Am Acad Child Adolesc Psychiatry 38: 112–113

    PubMed  CAS  Google Scholar 

  • Seifert J, Scheuerpflug P, Zillessen KE, Fallgatter A, Warnke A (2003) Electrophysiological investigation of the effectiveness of methylphenidate in children with and without ADHD. J Neural Transm 110: 821–829

    PubMed  CAS  Google Scholar 

  • Spencer TJ, Biederman J, Harding M, O’Donnel D, Faraone SV, Wilens TE (1996a) Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatray 35: 1460–1469

    Article  CAS  Google Scholar 

  • Spencer TJ, Biederman J, Wilens T, Harding M, O’Donnel D, Griffin S (1996b) Pharmacotherapy of attention-deficit hyperactivity disorder accross the life cycle. J Am Acad Child Adolesc Psychiatray 35: 409–432

    CAS  Google Scholar 

  • Spencer TJ, Biederman J, Coffrey B, Geller D, Wilens T, Faraone S (1999) The 4-year course of tic disorders in boys with attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 56: 842–847

    Article  PubMed  CAS  Google Scholar 

  • Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S (2001) An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11: 251–265

    Article  PubMed  CAS  Google Scholar 

  • Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil Ch, Conners CK, Potter WZ (2002) Results from 2 proof-of-concept, placebo-controlled studies of in children with attentiondeficit/hyperactivity disorder. J Clin Psychiatry 63: 1140–1147

    PubMed  CAS  Google Scholar 

  • Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper KM, Zimmerman B; Concerta Study Group (2006) Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry 45: 527–537

    Article  PubMed  Google Scholar 

  • Stopper H, Walitza S, Warnke A, Gerlach M (2008) Brief review of available evidence concerning the potential induction of genomic damage by methylphenidate. J Neural Transm 115: 331–334

    Article  PubMed  CAS  Google Scholar 

  • Sund AM, Zeiner P (2002) Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children? Nord J Psychiatry 56: 53–57

    Article  PubMed  Google Scholar 

  • The Tourette’s Syndrome Study Group (2002) Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 58: 527–536

    Google Scholar 

  • Tucha O, Prell S, Mecklinger L, Bormann-Kischkel C, Kübber S, Linder M, Walitza S, Lange KW (2006) Effects of methylphenidate on multiple components of attention in children with attention deficit hyperactivity disorder. Psychopharmacology 185: 315–326

    Article  PubMed  CAS  Google Scholar 

  • Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM (2008) Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 28: 783–800

    Article  PubMed  Google Scholar 

  • Vitiello B (2001) Long-Term effects of stimulant medication on the brain: Possible relevance to the treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11: 25–34

    Article  PubMed  CAS  Google Scholar 

  • Walitza S, Melfsen S, Herhaus G, Scheuerpflug P, Warnke A, Müller T, Lange KW, Gerlach M (2007a) Association of Parkinson’s disease with symptoms of attention deficit hyperactivity disorder in childhood. J Neural Transm [Suppl 72]: 311–315

    Google Scholar 

  • Walitza S, Werner B, Romanos M, Warnke A, Gerlach M, Stopper H (2007b) Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder? Environ Health Perspect 115: 936–940

    Article  PubMed  CAS  Google Scholar 

  • Warnke A, Wewetzer C (2003) Therapie des ADHS. Zeitschr Kinder-und Jugendmedizin 3: 155–160

    Google Scholar 

  • Warnke A, Renner TJ, Romanos M (2008) Arzneiverordnungen, Aufmerksamkeits-Defizit/Hyperaktivitätsstörung und Tic, 22. Aufl. Deutscher Ärzte-Verlag, Köln

    Google Scholar 

  • Wigal SB, McGough JJ, McCracken JT, Biederman J, Spencer TJ, Posner KL, Wigal TL, Kollins SH, Clark TM, Mays DA, Zhang Y, Tulloch SJ (2005) A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 9: 275–289

    Article  PubMed  Google Scholar 

  • Wigal SB, Biederman J, Swanson JM, Yang, Greenhill LL (2006) Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: Pooled analysis of 3 randomized, double-blind, place-bo-controlled studies Prim Care Companion J Clin Psychiatry 8: 352–360

    Google Scholar 

  • Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003) Does stimulant therapy of attentiondeficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111: 179–185

    Article  PubMed  Google Scholar 

  • Witcher JW, Long A, Smith B, Sauer JM, Heilgenstein J, Wilens T, Spencer T, Biederman J (2003) Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 13: 53–63

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kinder- und Jugendpsychiatrischer Dienst des Kantons Zürich, Neumünsterallee 9, 8032, Zürich

    Prof. Dr. med. Dipl.-Psych. S. Walitza (Ärztliche Direktorin)

  2. Oberarzt der Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Universität Würzburg, Füchsleinstraße 15, 97080, Würzburg

    Dr. med. M. Romanos MD & Dr. med. J. Seifert

  3. Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Julius-Maximilians-Universität, Füchsleinstraße 15, 97080, Würzburg

    Prof. Dr. med. A. Warnke (Direktor) & Prof. Dr. med. M. Gerlach

Authors
  1. Prof. Dr. med. Dipl.-Psych. S. Walitza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. M. Romanos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. med. J. Seifert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. med. A. Warnke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. med. M. Gerlach
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinik und Poliklinik für Kinder- und Jugendpsychiatrie, Würzburg, Deutschland

    Manfred Gerlach  & Andreas Warnke  & 

  2. Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie, Universität Ulm, Deutschland

    Claudia Mehler-Wex

  3. Kinder- und Jugendpsychiatrischer Dienst des Kantons Zürich, Zürich, Schweiz

    Susanne Walitza

  4. Kliniken der Stadt Köln, Klinik für Kinder- und Jugendpsychiatrie und Psychotherapie, Köln, Deutschland

    Christoph Wewetzer

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag/Wien

About this chapter

Cite this chapter

Walitza, S., Romanos, M., Seifert, J., Warnke, A., Gerlach, M. (2009). Psychostimulanzien. In: Gerlach, M., Warnke, A., Mehler-Wex, C., Walitza, S., Wewetzer, C. (eds) Neuro-Psychopharmaka im Kindes- und Jugendalter. Springer, Vienna. https://doi.org/10.1007/978-3-211-79275-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-79275-9_10

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-79274-2

  • Online ISBN: 978-3-211-79275-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation